Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Drug Does Not Improve Set of Cardiovascular Outcomes for Diastolic Heart Failure

Published: Tuesday, April 15, 2014
Last Updated: Tuesday, April 15, 2014
Bookmark and Share
NIH-supported study finds drug does appear to reduce hospitalizations for diastolic heart failure.

A drug that blocks the action of a key hormone did not significantly improve a set of cardiovascular outcomes for patients with diastolic heart failure, a condition in which the heart is stiffer than normal and has problems filling with blood, according to a study supported by the National Institutes of Health.

In terms of the study's primary aim, the results showed no difference in the overall combined endpoint treatments. The study did reduce the rate of heart failure hospitalizations, which was one of the endpoints, in the target population.

The drug, spironolactone, blocks the action of the hormone aldosterone, which is produced in excess in heart failure. The inexpensive generic drug currently is approved to treat patients with systolic heart failure, in which the heart muscle's pumping ability is reduced. There is no specific therapy for diastolic heart failure.

In the current trial, spironolactone did not improve the combined primary endpoints of cardiovascular death, hospitalization for heart failure, or aborted cardiac arrest. Aborted cardiac arrest is a stopped heart that is restarted by CPR or an implanted device.

NIH's National Heart, Lung, and Blood Institute (NHLBI) supported the work, which was published in the April 10 edition of the New England Journal of Medicine. The paper represents the primary results of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial.

Diastolic heart failure, also known as heart failure with preserved systolic function, is a common heart condition accounting for about half of all heart failure cases. The Centers for Disease Control and Prevention estimates that 5.7 million people in the United States have heart failure.

"Heart failure is the most common reason for hospital admissions in the Medicare population, and diastolic heart failure accounts for at least half of these admissions," said Dr. Bertram Pitt of the University of Michigan, Ann Arbor, TOPCAT's study chairman. "Given the high financial and societal costs of these hospitalizations, there is a critical need to find treatments to reduce them. However, no effective therapy for diastolic heart failure has been found to date."

The New England Research Institute and Brigham and Women's Hospital in Boston led the multi-center international research effort involving 3,445 participants, which makes it one of the largest diastolic heart failure trials to date. Researchers enrolled participants in 270 sites spread across the United States, Canada, Argentina, Brazil, the Republic of Georgia, and Russia. Trial participants were randomly placed on spironolactone or a matching placebo and followed for an average of three years.

For the spironolactone group, 319 participants experienced one of the primary outcomes versus 351 in the placebo group, a 9 percent reduction that did not reach statistical significance. For heart failure hospitalizations, 206 people in the spironolactone group were hospitalized versus 245 people in the placebo group, a statistically significant reduction of 16 percent.

"Although TOPCAT did not significantly decrease the combined endpoint or cardiovascular death, spironolactone is the first drug shown to reduce heart failure hospitalizations in this vulnerable population," said Brigham and Women's Hospital's Dr. Marc Pfeffer, the principal investigator.

Spironolactone showed no difference in other serious adverse events, such as dialysis, compared to placebo, although participants taking the drug had higher increased potassium levels than the control group. While use of spironolactone carries the risk of elevated blood potassium levels or reduced kidney function, these risks were low in TOPCAT and can be reduced in clinical practice with careful monitoring.

"This study is an important step in the effort to find effective treatments for diastolic heart failure patients," said Dr. Michael Lauer, director of the NHLBI's Division of Cardiovascular Sciences. "The study examined a broad cross-section of diastolic heart failure patients, and further data analysis may offer clues about sub groups that may particularly benefit from spironolactone treatment."

Initial analysis showed potentially different outcomes based on how a participant qualified for the study. Researchers used two methods to determine which patients with heart failure were eligible to enroll in the study. One method required looked for elevated levels of the hormone BNP, which is associated with more severe heart failure. The other method required looked at a person's history of heart failure hospitalization within the last year.

The study showed that participants enrolled via elevated BNP measurements who received spironolactone fared better in the composite of main outcomes than the BNP group enrolled in the placebo arm. Of the patients enrolled via the BNP criteria, there were 78 patients with events in the spironolactone arm and 116 patients with events in placebo group.

Further analysis showed significant geographic variation in event rates. For patients enrolled in Russia and the Republic of Georgia, 78 patients (10 percent) in the spironolactone arm and 71 patients (8 percent) in the placebo arm reached the composite primary endpoints. For patients in North and South America, 242 patients (27 percent) in the spironolactone arm and 280 patients (4 percent) in the placebo arm reached the composite primary endpoints.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,900+ scientific posters on ePosters
  • More Than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Study to Assess Shorter-Duration Antibiotics in Children
Physicians plan a clinical trial to evaluate whether short course anti-biotics are effective at treating CAP in children.
Wednesday, November 30, 2016
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
Wednesday, November 30, 2016
Antibody Protects Mice from Zika Infection
Researchers develop human-derived antibody protected pregnant mice and their developing fetuses from Zika infection.
Wednesday, November 23, 2016
Food Additives Promote Inflammation, Colon Cancer
Dietary emulsifiers promoted colon cancer in a mouse model by altering gut microbes and increasing gut inflammation.
Wednesday, November 23, 2016
Protein-Folding Gene Helps Heal Wounds
Researchers identified a protein that dramatically accelerates wound healing in animal models.
Wednesday, November 23, 2016
More Immunotherapy Options Approved for Lung Cancer
The FDA has approved a new immunotherapy drug for certain patients with non-small cell lung cancer.
Monday, November 21, 2016
Big Data for Infectious Disease Surveillance
NIH-led effort examines use of big data from health records and other digital sources for uses in infectious disease surveillance.
Tuesday, November 15, 2016
Potential Therapies Against Drug-Resistant Bacteria Identified
Researchers create new identification method for drug and drug combinations that may combat resistant infections.
Thursday, November 10, 2016
Testing Zika Vaccine in Humans Begins
The first of five planned clinical trials to test ZPIV vaccine in humans has begun.
Tuesday, November 08, 2016
Genetic Markers Predict Malaria Treatment Failure
By comparing 297 parasite genomes to a reference malaria parasite genome, researchers have identified two genetic markers that are strongly associated with the parasites’ ability to resist piperaquine.
Monday, November 07, 2016
Cannabinoid Receptor Structure Revealed
Scientists provided a detailed view of the primary molecule through which cannabinoids exert their effects on the brain. The findings might help guide the design of more targeted medicines with fewer side effects.
Wednesday, November 02, 2016
NIH Researchers Unveil New Wound-Healing Role for Protein-Folding Gene in Mice
The study found that topical treatment of an Hsp60-containing gel dramatically accelerates wound closure in a diabetic mouse model.
Friday, October 28, 2016
Ebola-Affected Countries Receive NIH Support
The National Institutes of Health has established a new program to further research capacity to study Ebola and other epidemics.
Thursday, October 27, 2016
Skin Patch to Treat Peanut Allergy
NIH-funded study suggests peanut protein patch is a safe and convenient method of treatment.
Thursday, October 27, 2016
Gene Editing Corrects Sickle Cell Mutation
Researchers demonstrate a potential pathway to developing gene-editing treatments for sickle cell disease.
Wednesday, October 26, 2016
Scientific News
Big Genetics in BC: The American Society for Human Genetics 2016 Meeting
Themes at this year's meeting ranged from the verification, validation, and sharing of data, to the translation of laboratory findings into actionable clinical results.
Stem Cells in Drug Discovery
Potential Source of Unlimited Human Test Cells, but Roadblocks Remain.
Cancer Genetics: Key to Diagnosis, Therapy
When applied judiciously, cancer genetics directs caregivers to the right drug at the right time, while sparing patients of unnecessary or harmful treatments.
Making Personalized Medicine a Reality
Groundbreaking technique developed at McMaster University is helping to pave the way for advances in personalized medicine.
Accelerating the Detection of Foodborne Bacterial Outbreaks
The speed of diagnosis of foodborne bacterial outbreaks could be improved by a new technique developed by researchers at the Georgia Institute of Technology.
Scientists Identify Unique Genomic Features in Testicular Cancer
The findings may shed light on factors in other cancers that influence their sensitivity to chemotherapy.
Top 10 Life Science Innovations of 2016
2016 has seen the release of some truly innovative products. To help you digest these developments, The Scientist have listed their top picks for the year.
BioCision Forms MedCision
The new company will focus on technologies for the management and automation of vital clinical processes.
Possible Treatment for Rare Vascular Disease
Researchers manage to reverse hereditary haemorrhagic telangiectasia in mice, if successful in humans it could lead to improved treatment for the disease.
Sweet Tooth Science - Chocolate Antioxidants
Researchers develop a faster and cheaper method to test for antioxidants in chocolate.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!